Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Journal of Neuro-Oncology

Volumn 92, Issue 2, 2009, Pages 165-175

  Santisteban, Marta ^a,b   Buckner, Jan C ^a   Reid, Joel M ^a   Wu, Wenting ^a   Scheithauer, Bernd W ^a   Ames, Matthew M ^a   Felten, Sara J ^a   Nikcevich, Daniel A ^c   Wiesenfeld, Martin ^d   Jaeckle, Kurt A ^e   Galanis, Evanthia ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Duluth CCOP   (United States)

^d Cedar Rapids Oncology Project CCOP   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Dexamethasone; Enzyme inducing antiepileptic drugs; Irinotecan; Pharmacokinetics; Recurrent gliomas

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEXAMETHASONE; DRUG METABOLITE; IRINOTECAN; NITROSOUREA; PHENOBARBITAL; PHENYTOIN; STEROID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GLIOMA; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BRAIN NEOPLASMS; CAMPTOTHECIN; DRUG INTERACTIONS; FEMALE; GLIOMA; GLUCURONIDES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 61349108073     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9749-4     Document Type: Article

References (35)

1. Levin VA, Ictech S, Hess KR (2007) Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 7:106. doi: 10.1186/1471-2407-7-106
2. Osoba D, Brada M, Yung WK, Prados MD (2000) Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36(14):1788-1795. doi: 10.1016/ S0959-8049(00)00165-9
3. Cloughesy TFPM, Mikkelsen T, Abbrey LE, Schiff D Yung WK et al (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008 ASCO Annual Meeting (Abstract 2010b)26(May 20 suppl):91s
4. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260(27):14873-14878
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51(16):4187-4191
6. Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516-1525
7. Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol 59(2):157-163. doi: 10.1023/ A:1019608404378
8. Cloughesy TF, Filka E, Nelson G et al (2002) Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol 25(2):204-208. doi: 10.1097/00000421-200204000-00022
9. Cloughesy TF, Filka E, Kuhn J et al (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97(9 Suppl):2381-2386. doi: 10.1002/ cncr.11306
10. Batchelor TT, Gilbert MR, Supko JG et al (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-oncol 6(1):21-27. doi: 10.1215/S1152851703000218
11. Prados MD, Yung WK, Jaeckle KA et al (2004) Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol 6(1):44-54. doi: 10.1215/ S1152851703000292
12. Prados MD, Lamborn K, Yung WK et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol 8(2):189-193. doi: 10.1215/ 15228517-2005-010
13. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779-8476. doi: 10.1200/JCO.2004.06.181
14. Quinn JA, Reardon DA, Friedman AH et al (2004) Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-oncol 6(2):145-153. doi: 10.1215/S1152851703000498
15. Reardon DA, Quinn JA, Rich JN et al (2004) Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncol 6(2):134-144. doi: 10.1215/S1152851703000413
16. Reardon DA, Quinn JA, Rich JN et al (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104(7):1478-1486. doi: 10.1002/cncr.21316
17. Loghin ME, Prados MD, Wen P et al (2007) Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clin Cancer Res 13(23):7133-7138. doi: 10.1158/ 1078-0432.CCR-07-0874
18. Feun LG, Marini A, Landy H et al (2007) Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. J Neurooncol 82(2):177-181. doi: 10.1007/s11060-006-9261-7
19. Reardon DA, Quinn JA, Vredenburgh J et al (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103(2):329-338. doi: 10.1002/cncr.20776
20. Vredenburgh JJ, Desjardins A, Herndon JEII et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259. doi: 10.1158/1078-0432.CCR-06-2309
21. Vredenburgh JJ, Desjardins A, Herndon JEII et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729. doi: 10.1200/JCO.2007.12.2440
22. Cloughesy TFPM, Mikkelsen T, Abbrey LE et al (2008) A phase, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT)on 6-month progression free survival (PFS6) in recurrent, treatment refractory glioblastoma (GBM). J Clin Oncol 26(20s):91s (Abstract 2010b)
23. Gilbert MR, Supko JG, Batchelor T et al (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9(8):2940-2949
24. Rothenberg ML, Cox JV, De Vore RF et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786-795. doi:10.1002/ (SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9
25. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
26. Pitot HC, Knost JA, Mahoney MR et al (2000) A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer 89(8):1699-1705. doi:10.1002/ 1097-0142(20001015)89:8<1699::AID-CNCR8>3.0.CO;2-T
27. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210-221
28. Hare CB, Elion GB, Houghton PJ et al (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39(3):187-191. doi: 10.1007/s002800050558
29. Nakatsu S, Kondo S, Kondo Y et al (1997) Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39(5):417-423. doi: 10.1007/s002800050592
30. Friedman HS, Keir ST, Houghton PJ (2003) The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 97(9 Suppl):2359-2362. doi: 10.1002/cncr.11305
31. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32(5):554-563. doi: 10.1345/aph.17332
32. Levy RH, Mather GG (1998) Metabolic enzymes and antiepileptic drug interactions. Adv Neurol 76:49-55
33. Taguchi T, Wakui A, Hasegawa K, et al (1990) Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 17(1):115-120
34. Herben VM, Schellens JH, Swart M et al (1999) Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 17(6):1897-1905
35. Stefanik DF, Fellows WK, Rizkalla LR et al (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55(2):91-100. doi: 10.1023/A:1013329832067